目的· 探讨MTA2 在子宫内膜癌中的表达及其与临床病理指标的相关性。方法· 采用GCBI 数据库分析MTA2 在各肿瘤组织中的mRNA 表达水平。采用免疫组织化学染色法检测MTA2、ER、PR、p53 和Ki-67 在119 例子宫内膜癌组织和21 例癌旁组织中的蛋白表达水平，并统计分析MTA2 表达与子宫内膜癌临床病理特征的关系及与ER、PR、p53 和Ki-67 表达的相关性。结果· 在GCBI 数据库中，MTA2 在包括子宫内膜癌在内的多数肿瘤中的表达均上调。MTA2 在子宫内膜癌患者组织中的表达显著高于癌旁组织表达水平（P=0.000）；MTA2 的表达与肿瘤分级有关(χ2=8.072，P=0.018）；MTA2 在子宫内膜癌中的表达与Ki-67 的表达呈正相关
（r=0.227，P=0.013），而与ER、PR 和p53 的表达无相关性。结论· MTA2 在子宫内膜癌发生和发展的过程具有重要作用，预示MTA2具有成为诊断分子的潜能。

Objective · To explore the expression of MTA2 in endometrial carcinomas and its correlation with clinicopathological features.
Methods · The GCBI database was used to analyse the MTA2 expression in most cancers. Immunohistochemical staining of MTA2, p53, ER, PR and Ki-
67 was performed in 119 endometrial carcinomas tissues and 21 corresponding adjacent non-neoplastic endometria. And the correlation between MTA2
expression and clinicopathological characteristics was evaluated as well as the correlation between MTA2 expression and the expression of ER, PR, p53
or Ki-67. Results · The expression of MTA2 was up-regulated in most of the tumors including endometrial carcinomas in GCBI database. MTA2 was
overexpressed in endometrial carcinoma compared with the adjacent normal tissues (P=0.000)，and the expression level was related to tumor grade
（χ2=8.072, P=0.018） and Ki-67 expression (r=0.227, P=0.013). Conclusion · MTA2 may act as an oncogene in endometrial carcinomas, and it is a promising target for diagnosis and treatment of endometrial carcinomas.